Literature DB >> 11924719

Kynureninase is a novel candidate gene for hypertension in spontaneously hypertensive rats.

Ken-ichi Mizutani1, Ken Sugimoto, Tomohiko Okuda, Tomohiro Katsuya, Toshiyuki Miyata, Tadashi Tanabe, Jitsuo Higaki, Toshio Ogihara, Yukio Yamori, Yasuyuki Tsujita, Naomi Tago, Naoharu Iwai.   

Abstract

The rostral ventrolateral medulla (RVLM) plays a critical role in the tonic and reflexive regulation of arterial blood pressure. Recent studies have demonstrated that injection of kynurenic acid (KYN) into the RVLM of spontaneously hypertensive rats (SHR) decreases arterial blood pressure. We hypothesized that a relative increase in the excitatory amino acid-mediated drive of RVLM vasomotor neurons in SHR may be due to derangement of one of the enzymes that affect the KYN level in the brain. We selected kynureninase, kynureninase hydroxylase, kynurenine aminotransferase type I, and kynurenine aminotransferase type II as candidates that may affect the KYN level in the brainstem. We conducted association studies between polymorphisms of these genes and blood pressure in an F2 population derived from SHR and Wistar-Kyoto rats (WKY). The cosegregation analysis indicated that only the kynureninase gene (KYNU) polymorphism influenced systolic blood pressure (SBP) and residuals of systolic blood pressure after adjusting for heart rate and body weight (RSBP). KYNU was found to be located on rat chromosome 3, and quantitative trait loci analysis at this locus indicated that the logarithms of the odds scores for KYNU in terms of SBP and RSBP were 2.0 and 3.3, respectively. This association with blood pressure decreased in proportion to the distance from KYNU. The expression level of KYNU mRNA in the brainstem was about 3.1 and 2.9 times higher in 10-week-old and 16-week-old SHR than in age-matched WKY, respectively. The increased expression of KYNU in SHR is thought to decrease the KYN level. KYNU seems to be one of the genes that contributes to hypertension in SHR.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11924719     DOI: 10.1291/hypres.25.135

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  10 in total

Review 1.  Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases.

Authors:  Ping Song; Tharmarajan Ramprasath; Huan Wang; Ming-Hui Zou
Journal:  Cell Mol Life Sci       Date:  2017-03-17       Impact factor: 9.261

2.  Severe intellectual disability, omphalocele, hypospadia and high blood pressure associated to a deletion at 2q22.1q22.3: case report.

Authors:  Milene Vianna Mulatinho; Cassio Luiz de Carvalho Serao; Fernanda Scalco; David Hardekopf; Sona Pekova; Kristin Mrasek; Thomas Liehr; Anja Weise; Nagesh Rao; Juan Clinton Llerena
Journal:  Mol Cytogenet       Date:  2012-06-11       Impact factor: 2.009

3.  GPR35 as a Novel Therapeutic Target.

Authors:  A E Mackenzie; J E Lappin; D L Taylor; S A Nicklin; G Milligan
Journal:  Front Endocrinol (Lausanne)       Date:  2011-11-09       Impact factor: 5.555

4.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Kati Maharry; Yue-Zhong Wu; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Kelsi B Holland; Susan P Whitman; Heiko Becker; Sebastian Schwind; Klaus H Metzeler; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 50.717

5.  Vasorelaxing Action of the Kynurenine Metabolite, Xanthurenic Acid: The Missing Link in Endotoxin-Induced Hypotension?

Authors:  Francesco Fazio; Albino Carrizzo; Luana Lionetto; Antonio Damato; Luca Capocci; Mariateresa Ambrosio; Giuseppe Battaglia; Valeria Bruno; Michele Madonna; Maurizio Simmaco; Ferdinando Nicoletti; Carmine Vecchione
Journal:  Front Pharmacol       Date:  2017-05-01       Impact factor: 5.810

6.  Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain-Its Possible Clinical Applications.

Authors:  Izabela Zakrocka; Katarzyna M Targowska-Duda; Artur Wnorowski; Tomasz Kocki; Krzysztof Jóźwiak; Waldemar A Turski
Journal:  Neurotox Res       Date:  2017-07-21       Impact factor: 3.911

7.  Study on the Antihypertensive Mechanism of Astragalus membranaceus and Salvia miltiorrhiza Based on Intestinal Flora-Host Metabolism.

Authors:  Cong Han; Yue-Hua Jiang; Wei Li; Yao Liu; Zhen-Qiang Qi
Journal:  Evid Based Complement Alternat Med       Date:  2019-07-21       Impact factor: 2.629

8.  Whole genome survey of copy number variation in the spontaneously hypertensive rat: relationship to quantitative trait loci, gene expression, and blood pressure.

Authors:  Fadi J Charchar; Michael Kaiser; Andrew J Bingham; Nina Fotinatos; Fahima Ahmady; Maciej Tomaszewski; Nilesh J Samani
Journal:  Hypertension       Date:  2010-03-15       Impact factor: 10.190

9.  Dissecting the genetic components of a quantitative trait locus for blood pressure and renal pathology on rat chromosome 3.

Authors:  H H Caline Koh-Tan; Mohammed Dashti; Ting Wang; Wendy Beattie; John Mcclure; Barbara Young; Anna F Dominiczak; Martin W McBride; Delyth Graham
Journal:  J Hypertens       Date:  2017-02       Impact factor: 4.844

10.  Genetic Variation and Hot Flashes: A Systematic Review.

Authors:  Carolyn J Crandall; Allison L Diamant; Margaret Maglione; Rebecca C Thurston; Janet Sinsheimer
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.